混合式角膜内皮移植术(H-DMEK):供体基质作为载体的牵拉植入技术结果
该回顾性介入病例系列评估了以DSAEK制备的供体基质为载体、使用EndoGlide Ultrathin DSAEK植入器行H-DMEK的结果与并发症。85眼(79例)中复杂眼占43.5%,术后4.7%因植片脱离需再次注气,6个月和12个月无既往眼病眼BCVA≥20/25者分别为44.7%和57.1%,6个月内皮细胞丢失32.2%±20.5%。
要点
- H-DMEK采用内皮面朝内构型的受控牵拉植入技术,可能尤其适用于复杂眼。
- 术后4.7%眼因植片脱离需再次注气,观察到2例植片失败。
- 6个月内皮细胞丢失32.2%±20.5%,后45例较前40例显著改善(p=0.012)。
核心结论
- H-DMEK提供了内皮面朝内构型的受控牵拉供体植入技术,可能尤其适用于复杂眼。
- 需更多研究证实该技术的长期内皮细胞丢失和植片存活情况。
研究设计与样本
- 回顾性介入病例系列,纳入大泡性角膜病变和Fuchs角膜内皮营养不良等接受H-DMEK的眼。
- 使用DSAEK制备的供体基质作为载体,经EndoGlide Ultrathin DSAEK供体植入器行双手牵拉技术。
- 纳入伴有引流管、小梁切除术、无晶状体、无虹膜、既往玻璃体切除、角膜移植或联合人工晶状体置换的复杂眼。
- 共85眼来自79例患者,其中大泡性角膜病变43.5%(n=37)、Fuchs角膜内皮营养不良28.2%(n=24)、植片失败24.7%(n=21)。
- 复杂眼行DMEK者37眼(43.5%)。
主要发现
- 4眼(4.7%)因植片脱离需再次注气,观察到2例植片失败。
- 无既往眼病眼BCVA≥20/25者在6个月为44.7%、12个月为57.1%。
- 总体内皮细胞丢失6个月为32.2%±20.5%。
- 内皮细胞丢失由前40例的37.2%±20.9%改善至后45例的24.2%±17.5%(p=0.012)。
关键数值与推荐
- 术后6个月总体内皮细胞丢失32.2%±20.5%。
- 前40例与后45例内皮细胞丢失分别为37.2%±20.9%与24.2%±17.5%(p=0.012)。
- 无既往眼病眼BCVA≥20/25者6个月44.7%、12个月57.1%。
- 因植片脱离需再次注气者4眼(4.7%),植片失败2例。
临床怎么用
- H-DMEK的受控牵拉植入技术可用于包括复杂眼在内的角膜内皮移植。
- 术后需关注植片脱离并必要时再次注气。
- 学习曲线可能影响内皮细胞丢失,后段病例内皮细胞丢失较低。
局限性
- 为回顾性病例系列。
- 长期内皮细胞丢失和植片存活尚需更多研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To evaluate the outcomes and complications of hybrid Descemet membrane endothelial keratoplasty (H-DMEK) using a Descemet stripping automated endothelial keratoplasty (DSAEK) pull-through donor inserter and donor stroma as carrier. METHODS: This was a retrospective interventional case series of eyes with bullous keratopathy (BK) and Fuchs endothelial corneal dystrophy (FECD), which underwent H-DMEK, performed using a bimanual pull-through technique using DSAEK-prepared donor stroma as carrier and the EndoGlide Ultrathin DSAEK donor insertion device. Complex cases with tube shunts, trabeculectomy, aphakia, aniridia, previous vitrectomy, keratoplasty or combined with intraocular lens exchange, were also included. The outcome measures were intraoperative and postoperative complications, best corrected visual acuity (BCVA) and endothelial cell loss after surgery. RESULTS: Of the 85 eyes from 79 patients, 43.5% (n=37) had BK, 28.2% (n=24) had FECD while 24.7% (n=21) had failed grafts. DMEK was performed in 37 complex eyes (43.5%). Four eyes (4.7%) required rebubbling for graft detachment and two cases of graft failure were observed. A BCVA of 20/25 or better was attained in 44.7% and 57.1% of eyes without pre-existing ocular pathology at 6 and 12 months, respectively. The overall endothelial cell loss was 32.2%±20.5% at 6 months, which improved from 37.2%±20.9% to 24.2%±17.5%, comparing the first 40 and last 45 cases (p=0.012). CONCLUSION: Hybrid DMEK offers a controlled 'pull-through' technique of donor insertion in the 'endothelium-in' configuration, which may be useful especially in complicated eyes. More studies are needed to confirm the long-term endothelial cell loss and graft survival associated with this technique.
引用
- Woo JH, Htoon HM, Tan D, et al. Hybrid Descemet Membrane Endothelial Keratoplasty (H-DMEK): results of a donor insertion pull-through technique using donor stroma as carrier. Br J Ophthalmol. 2020. PMID: 31949091. doi:10.1136/bjophthalmol-2019-314932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。